External factors
| External factors: |
Dexamethasone |
| Category: |
Chemical compounds |
| Tissue type: |
Tumor tissue |
| Experiment: |
CCK-8 assay//SA-β-gal activity assay//Cell morphological analysis//SAHF |
| Description: |
First, we noted that DDP caused remarkable and characteristic morphological alterations, including enlarged cellular size and a flattened shape in A549 cells and H292 cells, and DEX co-treatment attenuated these morphological alterations. DEX co-treatment also significantly affect the growth of A549 and H292 cell lines. DDP significantly induced increased SA-β-gal activity, and interestingly, DEX cotreatment decreased SA-β-gal activity compared with that of DDP treatment alone. DEX co-treatment could decrease the percentage of SAHFpositive cells compared with that of DDP treatment alone. |
Warning: Undefined variable $target_genes in
/data/html/Aging-ReG/public/browse_detail_2.php on line
385
Regulatory relationship
| Regulatory pathway:
|
p53-p21 |
| Official symbol(s): |
Warning: Undefined variable $name_all in /data/html/Aging-ReG/public/browse_detail_2.php on line 525
TP53-CDKN1A
|
| Pathway experiment: |
Western blot//qPCR//Luciferase reporter assay//SA-β-gal activity assay |
| Pathway description: |
After DDP treatment, p53 protein gradually accumulated, and effect was strikingly weakened in the presence of DEX. The same trend was also detected about the protein expression of p21CIP1, a well-established transcriptional target and downstream effector of p53 with functions in cell cycle arrest, senescence induction and apoptosis . Similarly, p53 mRNA level was also increased after DDP treatment, and DEX co-treatment attenuated this increase. Furthermore, we also used luciferase reporter assays to detect p53 promoter activity, and the analysis showed DEX co-treatment could also attenuate p53 promoter activity compared with that of DDP treated group.After 2 days of DDP treatment with or without pcDNA3.1-/p53, we investigated that overexpression of p53 could prevent the decrease of SA-β-Gal activity in DEX co-treatment group. |
Aging network
Annotation:
The green line represents Upregulation.
The purple line represents Downregulation.
The orange line represents Activation.
The yellow line represents Inhibition.
The gray line represents Unclear.